| 序号 | 修订前 第十四条 经依法登记，公司的经营范围： | 修订后 | | --- | --- | --- | | | 许可项目：药品生产；药品委托生产；药品批发；药品零售；药 品进出口；药物临床试验服务；第二类医疗器械生产；第三类医疗器 | 第十四条 经依法登记，公司的经营范围： 许可项目：药品生产；药品委托生产；药品批发；药品零售；药品进出口；药 | | | 械生产；第三类医疗器械经营。（依法须经批准的项目，经相关部门批 | 物临床试验服务；第一类医疗器械生产；第二类医疗器械生产；第三类医疗器械生 | | | 准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证 | 产；第三类医疗器械经营。（依法须经批准的项目，经相关部门批准后方可开展经营 | | | 件为准） | 活动，具体经营项目以相关部门批准文件或许可证件为准） | | 4. | 一般项目：医学研究和试验发展；细胞技术研发和应用；人体基 | 一般项目：医学研究和试验发展；细胞技术研发和应用；人体基因诊断与治疗 | | | 因诊断与治疗技术开发；工程和技术研究和试验发展；第二类医疗器 | 技术开发；工程和技术研究和试验发展；第一类医疗器 ...

深圳市卫光生物制品股份有限公司 2025 年第一次临时股东大会通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）第三届董事会第三十四 次会议决定于 2025 年 7 月 17 日在广东省深圳市光明区光明街道光侨大道 3402 号公司办公楼 4 楼会议室召开 2025 年第一次临时股东大会（以下简称本次股东 大会）。现就召开本次股东大会有关事宜通知如下： 一、召开会议的基本情况 1.股东大会届次：2025 年第一次临时股东大会。 证券代码:002880 证券简称:卫光生物 公告编号:2025-017 2.股东大会的召集人：公司董事会。 3.会议召开的合法合规性：公司第三届董事会第三十四次会议审议通过《关 于召开 2025 年第一次临时股东大会的议案》，决定召开公司 2025 年第一次临时 股东大会。本次股东大会的召开符合有关法律法规和《公司章程》的规定。 4.会议召开的日期、时间： （1）现场会议召开时间：2025 年 7 月 17 日 14:30 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-014 深圳市卫光生物制品股份有限公司 第三届董事会第三十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第三届董事会第三十四 次会议于2025年7月1日在公司办公楼4楼会议室以现场结合通讯方式召开。本次 会议应参加董事8名，实际参加董事8名，公司监事及高级管理人员列席了会议。 本次会议由董事长张战先生主持，会议的召集、召开和表决程序符合《中华人民 共和国公司法》（以下简称《公司法》）《中华人民共和国证券法》等有关法律、 法规及《公司章程》的规定。 二、董事会会议审议情况 会议经逐项审议，书面表决，审议通过了以下议案： 1.审议通过了《关于修订<公司章程>并办理工商变更登记的议案》； 为进一步完善公司治理结构，持续提升公司规范运作水平，根据《公司法》 《上市公司章程指引》《深圳证券交易所股票上市规则》等有关法律法规和规范 性文件的要求，结合公司实际情况，公司拟对《公司章程》进行修订。 公司董事会提请股东大会授权 ...

Core Viewpoint - The Chinese blood products industry is undergoing significant consolidation, with major players engaging in aggressive mergers and acquisitions to capture plasma resources, leading to the emergence of potential super giants in the sector [1][5]. Industry Landscape - The blood products industry in China is characterized by a "four-way" competitive landscape, dominated by four major groups: China National Pharmaceutical Group (Sinopharm), Haier Group, China Resources, and Hualan Biological Engineering [2][4]. - The industry has transitioned into a stock competition era since 2001, with new entrants needing to acquire existing licensed companies due to a moratorium on new licenses [2][3]. Mergers and Acquisitions - Significant acquisitions include China Resources' acquisition of Boya Biological for 4.8 billion yuan, Haier's 12.5 billion yuan acquisition of Shanghai Laishi, and Sinopharm's 4.5 billion yuan acquisition of Pilin Biological [1][2]. - The consolidation trend has led to a sharp increase in market concentration, with the top five companies' market share rising from under 50% in 2019 to over 70% by 2024 [4]. Plasma Collection and Utilization - Sinopharm's network includes 154 plasma collection stations, accounting for nearly 40% of the national total, with a collection volume of over 4,000 tons by mid-2025 [3]. - The cost structure of blood products heavily relies on raw plasma, which constitutes over 60% of total costs, making scale efficiency crucial for profitability [5][6]. Market Demand and Supply Gap - The domestic blood products market surpassed 60 billion yuan in 2023, with a demand gap of 4,000 tons, highlighting the need for leading companies to enhance their supply capabilities through technological upgrades [5][6]. - China's per capita consumption of blood products is significantly lower than that of developed countries, indicating a structural supply-demand imbalance [7][8]. Technological Advancements - Companies are shifting from a resource-driven model to a dual strategy of resource acquisition and research and development to overcome technological barriers and meet high-value product demands [9][10]. - Sinopharm and Hualan Biological are focusing on developing high-purity albumin and advanced coagulation factors, with significant investments in R&D to support these initiatives [10][11]. Future Outlook - The ongoing consolidation and technological advancements suggest that the Chinese blood products industry is on the verge of producing a super giant capable of competing globally [5][11]. - The combination of policy support, resource acquisition, and technological innovation is expected to drive the industry towards a more competitive and innovative future [10][11].

证券代码:002880 证券简称:卫光生物 公告编号:2025-013 深圳市卫光生物制品股份有限公司 关于获得医疗器械生产备案凭证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）近日获得深圳市市场监督 管理局出具的《第一类医疗器械生产备案凭证》，现将相关情况公告如下： 一、医疗器械生产备案凭证基本信息 1. 备案编号：粤深药监械生产备20250037号 2. 企业名称：深圳市卫光生物制品股份有限公司 3. 统一社会信用代码：91440300192471818P 6. 生产范围：2002版目录：6840体外诊断试剂 二、对公司的影响及风险提示 公司本次备案的产品属于第Ⅰ类医疗器械，公司获得上述产品的生产备案凭 证后，将增加公司可生产和销售的产品种类，对公司长期经营业绩具有积极影响， 对公司本年度财务状况不会产生重大影响。相关产品的生产和销售情况受到生产 进度、市场开发等因素的影响，存在不确定性，敬请广大投资者理性投资，注意投 资风险。 三、备查文件 《第一类医疗器械生产备案凭证》 特此公告。 深圳市卫光生物 ...

卫光生物（002880）公告，公司近日获得深圳市市场监督管理局出具的《第一类医疗器械生产备案凭 证》。备案编号为粤深药监械生产备20250037号，企业名称为深圳市卫光生物制品股份有限公司，统一 社会信用代码为91440300192471818P。生产地址为广东省深圳市光明区光明街道碧眼社区光侨大道 3402号办公楼一层，生产范围为2002版目录6840体外诊断试剂。公司获得上述产品的生产备案凭证后， 将增加公司可生产和销售的产品种类，对公司长期经营业绩具有积极影响。 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-012 深圳市卫光生物制品股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东大会召开期间无否决议案的情况； 2.本次股东大会未涉及变更以往股东大会已通过议案的情况。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议：2025 年 5 月 19 日 14:30。 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 19 日 9:15–9:25、9:30–11:30、13:00–15:00；通过深圳证券交易所互联网投票系 统投票的时间为 2025 年 5 月 19 日 9:15 至 15:00。 现场会议出席情况：参加本次股东大会现场会议的股东及股东代理人共 2 名， 代表有表决权的公司股份数合计为 164,430,000 股，占公司有表决权股份总数的 72.5000%。 网络投票情况：通过网络投票表决的股东共 100 名，代表有表决权的公司股份 数合计为 1,806,03 ...

上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2024 年度股东大会的 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 1 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2024 年度股东大会的 法律意见书 致：深圳市卫光生物制品股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受深圳市卫光生 物制品股份有限公司（以下简称"公司"）的委托，指派律师出席公司 2024 年度 股东大会（以下简称"本次股东大会"），并根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范 性文件以及现行有效的《深圳市卫光生物制品股份有限公司章程》（以下简称"《公 司章程》"）的相关规定，对本次股东大会相关法律事项进行见证并出具本法律意 见书。公司已向本所提供了 ...

Group 1: Plasma Collection and Supply - The company has implemented strategies to enhance plasma collection, including maintaining existing donors and expanding new donor recruitment, resulting in a plasma collection volume of 562 tons in 2024, an increase of 8.7% year-on-year [3][4] - Currently, the company operates 9 plasma collection stations, all fully operational, with plans to apply for new stations to increase collection capacity [3][4] - The company aims to ensure stable plasma supply by optimizing existing stations and actively seeking acquisition opportunities for quality plasma stations [8][9] Group 2: Research and Development - The company maintains a high level of R&D investment, which is crucial for sustaining technological leadership and competitive advantage, with a focus on enhancing the utilization rate of raw plasma and diversifying product offerings [4][5] - As of the end of 2024, the company has been granted 64 patents, including 24 invention patents and 40 utility model patents, reflecting its commitment to innovation [5] Group 3: Market Outlook and Value Creation - The global blood products industry is expected to grow due to increasing patient numbers and higher usage rates, with significant market potential in China as per capita usage remains low [8][9] - The company has a strategy to enhance its market value through cash dividends, stock bonuses, and employee stock ownership plans, while also focusing on investor relations and information disclosure [4][9]

Core Insights - The company reported a revenue of 1.203 billion yuan for 2024, representing a year-on-year increase of 14.75%, and a net profit attributable to shareholders of 254 million yuan, up 15.95% year-on-year [1] - In Q1 2025, the company experienced a slight decline in revenue to 225 million yuan, down 0.57% year-on-year, and a net profit of 44 million yuan, down 6.54% year-on-year, indicating some pressure on performance [1] Financial Performance - The company achieved double-digit growth in both revenue and profit for the full year, with a notable increase in non-recurring net profit, which grew by 25.97% year-on-year, indicating enhanced business profitability [2] - In Q4 2024, the company recorded revenue of 349 million yuan, a year-on-year increase of 19.02%, while the net profit attributable to shareholders was 71 million yuan, down 2.78% year-on-year [2][3] Cost Management - The company improved its gross margin to 41.88%, an increase of 0.56 percentage points year-on-year, while the period expense ratio decreased to 11.81%, down 1.49 percentage points year-on-year [4] - The sales expense ratio decreased to 2.42%, primarily due to a reduction in sales service fees, while the financial expense ratio increased to 1.69% due to higher interest expenses [4] Business Growth - The blood products segment generated revenue of 1.072 billion yuan in 2024, an increase of 8.80% year-on-year, with a gross margin of 43.04%, up 2.28 percentage points [5] - Key products such as human albumin and human immunoglobulin saw revenues of 459 million yuan and 431 million yuan, respectively, both showing year-on-year growth of over 15% [5] Plasma Collection - The company achieved a plasma collection volume of 562 tons in 2024, an increase of 8.7% year-on-year, and operates nine single plasma collection stations [6] - The company has initiated a new plasma station project and completed the acquisition of Waning Weiguang Single Plasma Co., achieving 100% control [6] Investment Outlook - The company is expected to achieve revenues of 1.347 billion yuan, 1.497 billion yuan, and 1.653 billion yuan for 2025-2027, with year-on-year growth rates of 12.0%, 11.1%, and 10.4% respectively [7] - The projected net profits for the same period are 299 million yuan, 345 million yuan, and 396 million yuan, with corresponding growth rates of 18.0%, 15.3%, and 14.8% [7]